Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01100268 · ClinicalTrials.gov registry record · Phase 2

Enhancing Attention in Adults With Compulsive Hoarding

A Phase 2 study of Hoarding Disorder, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
4
Enrollment target
2
Study locations

NCT01100268 is a Phase 2 study of Hoarding Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 4 participants, below the 39-participant average among 4 other Hoarding Disorder trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01100268, a Phase 2 study of Hoarding Disorder, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
4 participants
Enrollment target
2
Study locations

Study Summary

Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms.

Conditions Studied

Interventions

  • DRUG Methylphenidate ER

Study Locations (2)

Connecticut

  • Institute of Living - Hartford

New York

  • New York State Psychiatric Insitute - New York

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2010-04
Est. Completion 2011-04
Phase Phase 2

What the Registry Record Tells You About NCT01100268

The ClinicalTrials.gov registry entry for NCT01100268 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 4 other Hoarding Disorder trials with a reported enrollment target (90% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hoarding Disorder appearing as the primary indexed condition, and to 1 intervention - of which Methylphenidate ER is the first listed.

NCT01100268 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, New York.

Frequently Asked Questions

What is clinical trial NCT01100268 about?

NCT01100268 is a clinical study titled "Enhancing Attention in Adults With Compulsive Hoarding". Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms.

What is the current status of trial NCT01100268?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-04. Estimated completion is 2011-04.

What conditions does trial NCT01100268 study?

This clinical trial studies the following conditions: Hoarding Disorder.

What interventions are being tested in trial NCT01100268?

The interventions under investigation include: Methylphenidate ER (DRUG).

Who is sponsoring clinical trial NCT01100268?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01100268 being conducted?

This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hoarding Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.